• 1
    Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:60920.
  • 2
    Kaur D, Brightling C. OX40/OX40 ligand interactions in T-Cell regulation and asthma. Chest 2012; 141:4949.
  • 3
    Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004; 4:42031.
  • 4
    Liu Y-J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006; 203:26973.
  • 5
    Siddiqui S, Mistry V, Doe C, Stinson S, Foster M, Brightling C. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest 2010; 137:797804.
  • 6
    Seshasayee D, Lee WP, Zhou M et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest. 2007; 117:386878.
  • 7
    Cockcroft DW. Measure of airway responsiveness to inhaled histamine or methacholine; method of continuous aerosol generation and tidal breathing inhalation. In: Hargreave FE, Woolcock AJ, eds. Airway responsiveness: measurement and interpretation. Mississauga: Astra Pharmaceuticals Canada Ltd, 1985:228.
  • 8
    O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987; 136:74051.
  • 9
    Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987; 135:2647.
  • 10
    Pizzichini E, Pizzichini MM, Efthimiadis A et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154(2 Pt 1):30817.
  • 11
    Harada M, Hirota T, Jodo AI et al. Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma. Am J Respir Cell Mol Biol 2011; 44:78793.
  • 12
    Ohshima Y, Yang LP, Uchiyama T et al. OX40 costimulation enhances interleukin- 4 (IL-4) expression at priming and promotes the differentiation of naive human CD4 (+) T cells into high IL-4-producing effectors. Blood 1998; 1:333845.
  • 13
    Ito T, Wang YH, Duramad O et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005; 202:121323.
  • 14
    Burgess JK, Blake AE, Boustany S et al. CD40 and OX40 ligand are increased on stimulated asthmatic airway smooth muscle. J Allergy Clin Immunol. 2005; 115:3028.
  • 15
    Wang YH, Ito T, Wang YH et al. Maintenance and polarization of human Th2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 2006; 24:82738.
  • 16
    Jember AG, Zuberi R, Liu FT, Croft M. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J Exp Med 2001; 5:38792.
  • 17
    Arestides RS, He H, Westlake RM et al. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol 2002; 32:287480.
  • 18
    Hoshino A, Tanaka Y, Akiba H et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol 2003; 33:8619.
  • 19
    Salek-Ardakani S, Song J, Halteman BS et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003; 198:31524.
  • 20
    Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 1999; 62:181826.
  • 21
    Weinberg AD, Bourdette DN, Sullivan TJ et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996; 2:1839.
  • 22
    Parulekar A, Boomer JS, Patterson BM. et al. A randomized, controlled trial to evaluate inhibition of T cell costimulation in allergen induced airway inflammation. Am J Respir Crit Care Med 2013; 187:494501.
  • 23
    Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage-CD25+CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol. 2012; 188:150313.
  • 24
    Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:182834.
  • 25
    Gauvreau GM, Becker AB, Boulet LP et al. The effects of an anti-CD11a MAb, efalizumab on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol. 2003; 112:3318.
  • 26
    Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:21448.
  • 27
    Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet 2012; 18:6519.